Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease

Breast Cancer

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

Eur J Cancer

Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Belleville E, Wimberger P, Enzinger HM, Huebner H, Uhrig S, Hack CC, Krabisch P, Fasching PA, Wuerstlein R, Untch M, Ditsch N, Hein A, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, Goossens C, Engler T

doi: 10.1016/j.ejca.2025.115689

CHICAGO 2025

Breast Cancer

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

Breast Cancer

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

Ann Oncol

Mayer EL, Bidard FC, Park YH, Janni W, Ma C, Cristofanilli M, Iwata H, Bianchini G, Kalinsky K, Chia S, Brufsky A, Fasching PA, Nowecki Z, Chen SC, Pascual J, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Sohn JH, Zhu Y, Leddin I, Miralles MS, Bartlett CH, Turner N

doi: 10.1016/j.annonc.2025.10.006

SABCS 2025

Breast Cancer

DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer

ESMO 2025

Breast Cancer

SERENA-6: First-line camizestrant plus CDK4/6 inhibitor for emerging ESR1-mutated breast cancer shows consistent benefit in PROs

Breast Cancer

Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03

Ann Oncol

Saura C, Cortés J, Modi S, Kim SB, Hamilton E, Hurvitz SA, Krop IE, Curigliano G, Iwata H, Im SA, Herbolsheimer P, Karnoub M, Boran A, Kuwahara Y, Egorov A, André F

doi: 10.1016/j.annonc.2025.11.007

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Breast Cancer

Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis

Cancer Treat Rev

Escudero A, Bellet M, Saura C, Aguilera A, Papakonstantinou A, Tolosa P, García-Sáenz JÁ, Moreno F, López de Sá A, Schettini F, Seguí E, Gonzalez-Rodriguez M, Navarro V, Ferrero-Cafiero JM, González X, Hernando C, Matikas A, Prat A, Oliveira M, Pascual T, Villacampa G

doi: 10.1016/j.ctrv.2025.103063

RECOMMENDED

Breast Cancer

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study

★ 1 Recommended by Dr Andreas Müller, Faculty Member

J Clin Oncol

Valenza C, Zheng Y, Milano M, Trapani D, Giordano E, Guidi L, Berton Giachetti PPM, Boldrini L, Castellano G, Katrini J, Malagutti B, Antonarelli G, Conforti F, Pagan E, Bagnardi V, Kirkner GJ, Sangalli C, Dibble KE, Colleoni M, Regan MM, Munzone E, Curigliano G, Partridge AH

doi: 10.1200/JCO-25-01660

Related content

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer

SERENA-6: First-line camizestrant plus CDK4/6 inhibitor for emerging ESR1-mutated breast cancer shows consistent benefit in PROs

Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study